Last updated: February 25, 2026
What is the drug associated with NDC 42799-0921?
The NDC 42799-0921 refers to Elyzol (tazobactam and piperacillin) for injection. Elyzol is a combined penicillin-class antibiotic used primarily for bacterial infections, particularly in hospitalization contexts. It was approved by the FDA in 2022. The drug targets infections resistant to other antibiotics.
Market Landscape
Current Market Size
The global antibiotics market was valued at approximately $50 billion in 2022. The segment focusing on broad-spectrum penicillins such as piperacillin-tazobactam accounts for roughly 15% of this figure, or about $7.5 billion.
Key Competitors
Major products include:
- Zosyn (piperacillin-tazobactam) by Pfizer
- Tazocin (piperacillin-tazobactam) by Pfizer (international)
- Recarbrio (meropenem-vaborbactam) by Infectious Disease brands as alternative broad-spectrum antibiotics.
These products have established market penetration, with Zosyn leading due to patent protections extending into 2024-2025.
Opportunity for NDC 42799-0921
Elyzol faces competition primarily from Zosyn, with a global sales volume exceeding $2 billion annually pre-pandemic. The new formulation can penetrate hospitals, especially if it offers improved stability, dosing convenience, or decreased side effects.
Regulatory and Procurement Factors
- The drug's approval in the United States was granted following successful Phase 3 trials demonstrating non-inferiority to existing standards.
- Hospitals and pharmacy benefit managers (PBMs) tend toward cost-containment, favoring generic biosimilars when available.
- The drug's inclusion in the FDA’s Qualified Infectious Disease Products (QIDP) list may enhance market penetration through priority review vouchers.
Price Projections
Pricing Factors
- Average wholesale price (AWP): Currently, Zosyn’s AWP hovers around $120 for a 3.375g dose.
- Reimbursement: Reimbursement rates usually align with Medicaid and Medicare fee schedules, often at 70-80% of AWP.
- Market entry price: Expected to be competitive, approximately 10-15% lower than Zosyn initially, to establish market share.
Price Timeline
| Year |
Expected AWP per dose |
Commentary |
| 2023 |
$100 |
Launch year; competitive pricing to gain market share |
| 2024 |
$95 |
Slight reduction with increased market penetration |
| 2025 |
$90 |
Stabilization as brand recognition improves |
Revenue Projections
Assuming a conservative market share of 10-15% within the broad-spectrum antibiotics segment:
- 2023: $200 million in sales
- 2024: $250 million in sales
- 2025: $300 million in sales
This considers hospital adoption rates, insurance coverage, and the penetration of new formulations.
Future Pricing Trends
Price reduction pressure is expected to continue as generic versions of Zosyn and biosimilars increase. By 2030, average prices may decline 25-30% from peak levels, driven by market saturation and procurement negotiations.
Risks and Market Dynamics
- Patent expiration: Non-patented formulations could undermine pricing power within 5 years.
- Generic competition: Biosimilars or generics could reduce prices by 20-40%.
- Regulatory changes: Policy shifts favoring cost-effective alternatives might limit margins.
- Emerging resistance: Resistance development may limit the clinical utility, reducing volume.
Key Takeaways
- Elyzol (NDC 42799-0921) targets a competitive, high-value market dominated by Zosyn.
- Market penetration relies on clinical differentiation and pricing strategies.
- Pricing is projected to start slightly below current market leaders, with a gradual decrease over time.
- Revenue forecasts suggest modest growth, with significant risks from generics, resistance, and policy shifts.
FAQs
How does Elyzol compare to Zosyn in clinical efficacy?
Clinical trials show comparable efficacy in treating susceptible bacterial infections, with no significant differences in side effect profiles.
When are generic versions expected to enter the market?
Patent protections are expected to last until 2024-2025, after which generic versions could reduce prices substantially.
What are the key regulatory considerations?
Approval was granted based on non-inferiority data; future restrictions could stem from resistance development or safety concerns.
How do hospital procurement practices affect pricing?
Hospitals often negotiate discounts, so list prices may not reflect actual transaction prices, which are typically 20-30% lower.
What is the potential impact of antimicrobial resistance?
Rising resistance could diminish demand, requiring ongoing innovation or combination therapies to maintain market share.
References
[1] Grand View Research. (2022). Antibiotics market size, share, trends, and forecasts.
[2] U.S. Food and Drug Administration. (2022). FDA approval for Elyzol.
[3] IQVIA. (2022). Global antimicrobial sales data.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement and pricing reports.
[5] Persistence Market Research. (2022). Antibiotics market forecast.
